Bioretec Ltd - Manager's transactions - Paavola
Bioretec Ltd - Manager's transactions - Paavola |
| [27-April-2026] |
TAMPERE, Finland, April 27, 2026 /PRNewswire/ -- Bioretec Oy Company Release 27 April 2026 at 4:00 p.m. EEST Bioretec Oy - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Tuukka Paavola Position: Chief Financial Officer Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 153482/4/4 ____________________________________________ Transaction date: 2026-04-24 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000480454 Nature of transaction: SUBSCRIPTION Transaction details (1): Volume: 2000000 Unit price: 0.01 EUR Aggregated transactions (1): Volume: 2000000 Volume weighted average price: 0.01 EUR Further enquiries Tuukka Paavola, CFO, +358 50 386 0013 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Information about Bioretec Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients. Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions. To learn more about Bioretec, visit www.bioretec.com This information was brought to you by Cision http://news.cision.com https://news.cision.com/bioretec/r/bioretec-ltd---manager-s-transactions---paavola,c4340710
| ||
Company Codes: Helsinki:BRETEC,ISIN:FI4000480454 |
View original content:
